
-
Study finds women have higher genetic risk of depression
-
Dolly Parton's sister calls for fan prayers over health issues
-
On Trump's orders, 200 troops from Texas arrive in Illinois
-
Two bodies found, two missing after Madrid building collapse
-
Panthers raise banner as NHL three-peat bid opens with win
-
Nobel physics laureate says Trump cuts will 'cripple' US research
-
UFC star McGregor suspended 18 months over missed drug tests
-
Trump talks up Canada trade deal chances with 'world-class' Carney
-
Ecuador president unharmed after apparent gun attack on motorcade
-
Lyon exact revenge on Arsenal, Barca thrash Bayern in women's Champions League
-
Trump says 'real chance' to end Gaza war as Israel marks attacks anniversary
-
Gerrard brands failed England generation 'egotistical losers'
-
NFL fines Cowboys owner Jones $250,000 over gesture to fans
-
Bengals sign veteran quarterback Flacco after Burrow injury
-
New prime minister inspires little hope in protest-hit Madagascar
-
Is Trump planning something big against Venezuela's Maduro?
-
EU wants to crack down on 'conversion therapy'
-
French sex offender Pelicot says man who abused ex-wife knew she was asleep
-
Trump says 'real chance' to end Gaza war as Israel marks Oct 7 anniversary
-
UK prosecutors to appeal dropped 'terrorism' case against Kneecap rapper
-
Spain, Inter Miami star Alba retiring at end of season
-
EU targets foreign steel to rescue struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarters
-
Trump talks up Canada deal chances with visiting PM
-
Knight rides her luck as England survive Bangladesh scare
-
Pro-Gaza protests flare in UK on anniversary of Hamas attack
-
Top rugby unions warn players against joining rebel R360 competition
-
Outcast Willis 'not overthinking' England absence despite Top 14 clean sweep
-
Trump says 'real chance' of Gaza peace deal
-
Macron urged to quit to end France political crisis
-
No.1 Scheffler seeks three-peat at World Challenge
-
Canadian PM visits Trump in bid to ease tariffs
-
Stocks falter, gold shines as traders weigh political turmoil
-
Senators accuse US attorney general of politicizing justice
-
LeBron's 'decision of all decisions' a PR stunt
-
Observing quantum weirdness in our world: Nobel physics explained
-
WTO hikes 2025 trade growth outlook but tariffs to bite in 2026
-
US Supreme Court hears challenge to 'conversion therapy' ban for minors
-
Italy's Gattuso expresses Gaza heartache ahead of World Cup qualifier with Israel
-
EU targets foreign steel to shield struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarterfinals
-
Stocks, gold rise as investors weigh AI boom, political turmoil
-
Swiatek coasts through Wuhan debut while heat wilts players
-
Denmark's Rune calls for heat rule at Shanghai Masters
-
Japanese football official sentenced for viewing child sexual abuse images
-
Stocks, gold steady amid political upheaval
-
'Veggie burgers' face grilling in EU parliament
-
Trio wins physics Nobel for quantum mechanical tunnelling
-
Two years after Hamas attack, Israelis mourn at Nova massacre site
-
German factory orders drop in new blow to Merz

Modular Medical Announces MODD1 Cartridge Line Validated for Human-Use Production
-Line has been in production at risk since early July
- Production to continue until late August when conversion to Pivot manufacturing will begin
SAN DIEGO, CA / ACCESS Newswire / August 4, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced that the MODD1 cartridge line has been validated for human-use production in the United States.
"This is an important milestone for scaling up our manufacturing infrastructure to support our commercial pilot for MODD1 and, eventually, our 3ml Pivot tubeless patch pump launch," stated Jeb Besser, CEO of Modular Medical. "While we encountered significant delays with the initial shipment of equipment for the manufacturing line to our contract manufacturing site in Mexico, all equipment for the controller line has been installed and validation is underway. We continue to target controller line validation in October for MODD1 with the commercial pilot for MODD1 to follow immediately thereafter."
The ability to scale production is a key differentiator in the pump space, especially given the much higher volumes required for a patch pump. Modular Medical's simple, low-cost platform was designed from the ground up for high volume manufacturing.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to obtain the validations required to manufacture products for human use; the timing of achievement of such validations, if at all; the Company's ability to convert patients to use its pump products; and the occurrence of future events or circumstances, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
About Modular Medical
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
[email protected]
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire
M.Fischer--AMWN